Core Scientific (Core Scientific) EBIT : $84.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Core Scientific EBIT?

Core Scientific's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $225.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $84.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Core Scientific's annualized ROC % for the quarter that ended in Mar. 2024 was 32.34%. Core Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 144.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Core Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.25%.

Core Scientific EBIT Historical Data

The historical data trend for Core Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core Scientific EBIT Chart

Core Scientific Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-11.69

-7.77

107.43

-2,066.58

-159.57

Core Scientific Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial											-0.13	9.84	-38.84	-111.44	224.98

Competitive Comparison of Core Scientific's EBIT

For the Software - Infrastructure subindustry, Core Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Core Scientific's EV-to-EBIT Distribution in the Software Industry

For the Software industry and Technology sector, Core Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Core Scientific's EV-to-EBIT falls into.

Core Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $84.6 Mil.

Core Scientific (OTCPK:CORZQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Core Scientific's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	242.888 * ( 1 - 0.1% )	/	( (775.951	+	724.407)	/ 2 )
=	242.645112	/	750.179
=	32.34 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	712.156	-	327.612	-	( 50.409	-	max(0, 488.423	-	97.016	+	50.409	))
=	775.951

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	813.968	-	84.386	-	( 98.125	-	max(0, 138.145	-	143.32	+	98.125	))
=	724.407

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Core Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	899.936	/	( ( (593.275 + max(-303.768, 0))	+	(653.736 + max(-63.98, 0)) )	/	2 )
=	899.936	/	( ( 593.275	+	653.736 )	/	2 )
=	899.936	/	623.5055
=	144.33 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.001	+	0	+	39.448)	-	(327.612	+	9.83	+	6.775)
=	-303.768

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.107	+	0	+	44.088)	-	(84.386	+	9.25	+	15.539)
=	-63.98

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Core Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	84.551	/	1166.287
	=	7.25 %

Core Scientific EBIT Related Terms

Thank you for viewing the detailed overview of Core Scientific's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Core Scientific (Core Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Core Scientific Inc (OTCPK:CORZQ) » Definitions » EBIT

Comparable Companies

BAND PRTH RXT LSAK CGNT OSPN LVOX BLZE REKR TCX MSFT ORCL ADBE PANW SNPS VMW FTNT CRWD PLTR SQ

Traded in Other Exchanges

CORZ:USA

Address

210 Barton Springs Road, Austin, TX, USA, 78704

Website

https://www.corescientific.com

Core Scientific Inc is engaged in Blockchain and AI Infrastructure, Digital Asset Self-Mining, Premium Hosting, Blockchain Technology, and Artificial Intelligence related services. The business operates in two segments being; Equipment Sales and Hosting which consists of blockchain infrastructure, third-party hosting business and equipment sales to customers. Mining segment consists of digital asset mining for its account. The blockchain business generates revenue from the sale of consumption-based contracts and by providing hosting services. The digital asset mining segment earns revenue from operating a firm's owned computer equipment as part of a pool of users that process transactions conducted on one or more blockchain networks. In exchange, it receives digital currency assets.

Executives

Adam Taylor Sullivan	officer: President	C/O CORE SCIENTIFIC, INC., 2407 S. CONGRESS AVENUE, AUSTIN TX 78704
Darin Feinstein	director, 10 percent owner, officer: Chief Vision Officer	2800 NORTHUP WAY, SUITE 220, BELLEVUE WA 98004
Sterling Denise Marie Brucia	officer: Chief Financial Officer	C/O CORE SCIENTIFIC, INC., 201 BARTON SPRINGS ROAD, AUSTIN TX 78704
Matt Minnis	director	2800 NORTHUP WAY, SUITE 220, BELLEVUE WA 98004
Brian Neville	officer: Chief Accounting Officer	C/O CORE SCIENTIFIC, INC., 2800 NORTHROP WAY, BELLEVUE WA 98004
Todd M Duchene	officer: EVP, GC and Secretary	847 GIBRALTAR DR., MILPITAS CA 95035
Michael Trzupek	officer: Chief Financial Officer	2800 NORTHUP WAY, SUITE 220, BELLEVUE WA 98004
Stacie Olivares	director	2525 E. CAMELBACK RD., STE 850, PHOENIX AZ 85016
Jarvis V. Hollingsworth	director	100 WEST HOUSTON STREET, SAN ANTONIO TX 78205
Michael J Levitt	director, officer: Chief Executive Officer	KAYNE ANDERSON CAPITAL ADVISORS, L.P., 1800 AVENUE OF THE STARS, 3RD FLOOR, LOS ANGELES CA 90067
Dr Kneeland Youngblood	director	C/O GAP, INC., 2 FOLSOM ST., SAN FRANCISCO CA 94105
John P Mcgarrity	officer: General Counsel and Secretary	321 N. CLARK STREET, CHICAGO IL 60054
Sullivan Colleen	director	420 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Theodore J Brombach	10 percent owner	321 N. CLARK STREET, CHICAGO IL 60054
Patrick C Eilers	director, 10 percent owner, officer: Chief Executive Officer	THREE FIRST NATIONAL PLAZA STE 3800, CHICAGO IL 60602